IL302294A - Use of an anti-cd19 antibody to treat autoimmune disease - Google Patents

Use of an anti-cd19 antibody to treat autoimmune disease

Info

Publication number
IL302294A
IL302294A IL302294A IL30229423A IL302294A IL 302294 A IL302294 A IL 302294A IL 302294 A IL302294 A IL 302294A IL 30229423 A IL30229423 A IL 30229423A IL 302294 A IL302294 A IL 302294A
Authority
IL
Israel
Prior art keywords
patient
nmosd
vib551
antibody
months
Prior art date
Application number
IL302294A
Other languages
English (en)
Hebrew (he)
Original Assignee
Viela Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viela Bio Inc filed Critical Viela Bio Inc
Publication of IL302294A publication Critical patent/IL302294A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL302294A 2020-10-29 2021-10-29 Use of an anti-cd19 antibody to treat autoimmune disease IL302294A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063107182P 2020-10-29 2020-10-29
US202163143541P 2021-01-29 2021-01-29
US202163178286P 2021-04-22 2021-04-22
PCT/US2021/057443 WO2022094334A1 (en) 2020-10-29 2021-10-29 Use of an anti-cd19 antibody to treat autoimmune disease

Publications (1)

Publication Number Publication Date
IL302294A true IL302294A (en) 2023-06-01

Family

ID=81384348

Family Applications (1)

Application Number Title Priority Date Filing Date
IL302294A IL302294A (en) 2020-10-29 2021-10-29 Use of an anti-cd19 antibody to treat autoimmune disease

Country Status (10)

Country Link
US (1) US20230287114A1 (https=)
EP (1) EP4237447A4 (https=)
JP (1) JP2023549075A (https=)
KR (1) KR20230097118A (https=)
AU (1) AU2021368769A1 (https=)
CA (1) CA3197022A1 (https=)
IL (1) IL302294A (https=)
MX (1) MX2023004794A (https=)
TW (1) TW202233676A (https=)
WO (1) WO2022094334A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023534916A (ja) * 2020-06-30 2023-08-15 ビエラ バイオ インコーポレイテッド 視神経脊髄炎スペクトラム障害を治療する方法
WO2025202213A1 (en) 2024-03-26 2025-10-02 Institut National de la Santé et de la Recherche Médicale Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201401465D0 (en) * 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease
MX2021012870A (es) * 2019-04-24 2022-01-18 Viela Bio Inc Uso de un anticuerpo anti cúmulo de diferenciación 19 (cd19) para tratar enfermedades autoinmunitarias.
JP2023534916A (ja) * 2020-06-30 2023-08-15 ビエラ バイオ インコーポレイテッド 視神経脊髄炎スペクトラム障害を治療する方法

Also Published As

Publication number Publication date
EP4237447A1 (en) 2023-09-06
KR20230097118A (ko) 2023-06-30
EP4237447A4 (en) 2024-07-17
WO2022094334A1 (en) 2022-05-05
JP2023549075A (ja) 2023-11-22
TW202233676A (zh) 2022-09-01
AU2021368769A9 (en) 2024-05-30
MX2023004794A (es) 2023-09-15
CA3197022A1 (en) 2022-05-05
US20230287114A1 (en) 2023-09-14
AU2021368769A1 (en) 2023-06-08

Similar Documents

Publication Publication Date Title
Pittock et al. Hope for patients with neuromyelitis optica spectrum disorders—from mechanisms to trials
Prasad et al. What you need to know about AQP4, MOG, and NMOSD
Herbort Jr et al. Precise, simplified diagnostic criteria and optimised management of initial-onset Vogt–Koyanagi–Harada disease: an updated review
IL274462A (en) Anti-b7-h1 antibodies for treating tumors
Chen et al. Details and outcomes of a large cohort of MOG-IgG associated optic neuritis
IL193775A (en) Uses of pharmaceutical compositions containing natalizumab
Sahraian et al. Diagnosis and management of Neuromyelitis Optica Spectrum Disorder (NMOSD) in Iran: A consensus guideline and recommendations
IL302294A (en) Use of an anti-cd19 antibody to treat autoimmune disease
KR20240107372A (ko) 사트랄리주맙을 사용하는 중추 신경계(cns)의 탈수초화 질환의 치료
Fu et al. Efficacy of plasma exchange treatment for demyelinating optic neuritis associated with various serum antibodies: a prospective cohort study
Sechi NMOSD and MOGAD
Valencia-Sanchez et al. Emerging Targeted Therapies for Neuromyelitis Optica Spectrum Disorders: C. Valencia-Sanchez et al.
Wingerchuk et al. Aligning payer and provider strategies with the latest evidence to optimize clinical outcomes for patients with neuromyelitis optica spectrum disorder
Ji et al. Selectively targeting disease-restricted secretogranin III to alleviate choroidal neovascularization
Behera et al. Bilateral optic neuritis and facial palsy following COVID-19 infection
IL297640A (en) Methods and combinations for cancer treatment using immune checkpoint inhibitor antibodies
IL298299A (en) Treatment of cardiometabolic disease with inhibitors of type i interferon signalling
IL296564A (en) Combination of an lsd-1 inhibitor and nivolumab for use in treating sclc or sqnsclc
Yan et al. Clinical and imaging features and treatment response of anti-NMDAR encephalitis combined with MOGAD
IL317055A (en) METHOD FOR TREATING MYASTHENIA GRAVIS WITH TACI-FC FUSION PROTEIN
IL300415A (en) Methods for treating multiple sclerosis with ocralizumab
Zhong et al. FLAMES overlaying anti-N-methyl-D-aspartate receptor encephalitis: a case report and literature review
JP2023534916A (ja) 視神経脊髄炎スペクトラム障害を治療する方法
Rowe et al. Autoimmune neuro-ophthalmic disorders: pathophysiologic mechanisms and targeted biologic therapies
HK40096777A (zh) 使用抗cd19抗体治疗自身免疫性疾病